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ABSTRACT
Context: OnabotulinumtoxinA and mirabegron have
recently gained marketing authorisation to treat
symptoms of overactive bladder (OAB).
Objective: To evaluate the relative efficacy of
mirabegron and onabotulinumtoxinA in patients with
idiopathic OAB.
Design: Network meta-analysis.
Data sources: A search of 9 electronic databases,
review documents, guidelines and websites.
Methods: Randomised trials comparing any licensed
dose of onabotulinumtoxinA or mirabegron with each
other, anticholinergic drugs or placebo were eligible
(19 randomised trials were identified). 1 reviewer
extracted data from the studies and a second reviewer
checked the data. Candidate trials were assessed for
similarity and networks were developed for each
outcome. Bayesian network meta-analysis was
conducted using both fixed-effects and random-effects
models. When there were differences in mean baseline
values between mirabegron and onabotulinumtoxinA
trials they were adjusted for using network meta-
regression (NMR).
Results: No studies directly comparing
onabotulinumtoxinA to mirabegron were identified. A
network was created for each of the 7 outcomes, with
3–9 studies included in each individual network. The
trials included in the networks were broadly similar.
Patients in the onabotulinumtoxinA trials had more
urinary incontinence and urgency episodes at baseline
than patients in the mirabegron trials and these
differences were adjusted for using NMR. Both
onabotulinumtoxinA and mirabegron were more
efficacious than placebo at reducing the frequency of
urinary incontinence, urgency, urination and nocturia.
OnabotulinumtoxinA was more efficacious than
mirabegron (50 and 25 mg) in completely resolving
daily episodes of urinary incontinence and urgency and
in reducing the frequency of urinary incontinence,
urgency and urination. NMR supported the results of
the network meta-analysis.
Conclusions: In the absence of head-to-head trials
comparing onabotulinumtoxinA to mirabegron, this
indirect comparison indicates that onabotulinumtoxinA
may be superior to mirabegron in improving symptoms
of urinary incontinence, urgency and urinary frequency
in patients with idiopathic OAB.
INTRODUCTION
Overactive bladder (OAB) is deﬁned by the
International Continence Society (ICS) as
“urgency, with or without urgency incontin-
ence usually with increased daytime fre-
quency and nocturia.”1 The aetiology of
OAB is diverse, but in the majority of
instances the underlying cause of OAB is
unclear (idiopathic).
Strengths and limitations of this study
▪ This study represents the first evaluation of the
relative benefits of onabotulinumtoxinA com-
pared with mirabegron in adults with idiopathic
overactive bladder.
▪ The results enhance the current evidence base,
assisting patients and healthcare providers to
make more informed decisions about treatment
options.
▪ In the absence of head-to-head trials, the ana-
lyses relied on indirect comparisons, which
make underlying assumptions about the similar-
ity of the trials and participants included in the
network.
▪ Network meta-regression was applied to the
changes from baseline in urinary incontinence
episodes and urgency episodes, in order to
adjust for differences in the baseline values of
these outcomes. Because individual patient data
were available for onabotulinumtoxinA trials, but
not for mirabegron trials, it was assumed that
the relationship between baseline values and
change from baseline was the same across all
included trials.
▪ This analysis did not include an assessment of
adverse events.
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OAB and urinary incontinence (UI) are associated
with recurrent urinary tract infection and skin break-
down, infection, and/or ulceration.2 3 UI is also asso-
ciated with considerable social stigma, may contribute to
loss of independence, and signiﬁcantly reduces
health-related quality of life (HRQoL).2 4 In addition,
there seems to be a relationship between symptoms of
OAB and the risk of falls and fractures among elderly
patients.5
Although there is no cure for OAB, symptoms may be
managed through a range of approaches. Treatment
generally follows a stepped approach from conservative
to more invasive interventions.6–8 Treatment pathways
initially focus on lifestyle intervention (weight loss, caf-
feine and alcohol reduction), behavioural techniques
(bladder training, bladder control strategies, pelvic ﬂoor
muscle training and ﬂuid management) and oral
pharmacotherapy, predominantly anticholinergics (in
some countries, mirabegron is available as an initial
option). If these therapies fail then other options
include mirabegron, botulinum toxin injection, sacral
nerve stimulation, posterior tibial nerve stimulation and
surgery. The National Institute for Health and Care
Excellence recommends no more than two oral agents
for UI.9 However, despite the recognition that alternative
treatments are available which may be more suitable,
patients tend to continue to cycle on oral drugs without
further improvement.10 The physical and psychological
sequelae of inadequately managed OAB can be debilitat-
ing and have a signiﬁcant impact on patients’ overall
HRQoL.11 12
The most recently approved agents to treat OAB are
onabotulinumtoxinA (BOTOX; Allergan, Inc) and mira-
begron (Myrbetriq, Betmiga; Astellas Pharma).13–16 A
recent systematic review and mixed treatment compari-
son has been published comparing mirabegron 50 mg
to antimuscarinics for the management of OAB.17
However, to date, there have been no such comparisons
that have included onabotulinumtoxinA.
In the absence of head-to-head data, indirect treat-
ment comparisons provide the best available evidence to
allow for informed decisions between different treat-
ments. The objective of this study was to evaluate the
relative clinical efﬁcacy of the licensed dose of
onabotulinumtoxinA (100 U) compared with mirabe-
gron (25 and 50 mg) in adults with OAB via an indirect
treatment comparison.
METHODS
Eligibility criteria
The eligibility of studies for inclusion in the network
meta-analysis (NMA) was established a priori and docu-
mented in a project protocol. Eligible studies were ran-
domised controlled trials, published in English, which
compared onabotulinumtoxinA or mirabegron with
each other, anticholinergic drugs, or placebo in adults
with idiopathic OAB (table 1).
Study identification and selection
The search strategies for this update review were
informed by a previous literature review,18 with add-
itional terms identiﬁed through a range of approaches,
including scanning background literature, browsing
database thesauri and use of the online PubMed
PubReminer tool (http://hgserver2.amc.nl/cgi-bin/
miner/miner2.cgi). A search of nine databases (from
inception to the end of August 2013), relevant reviews
and guidelines, and websites was conducted to identify
all relevant trials that might contribute to the NMA.
Details of the information resources searched and elec-
tronic search strategies for MEDLINE and EMBASE,
including any limits used, are reported in the online
supplementary appendices A1–A2. The search strategies
for other data sources are available on request.
Search results were assessed for relevance according to
the eligibility criteria, with records screened in several
stages (ﬁgure 1). One reviewer selected the studies and
a second reviewer carried out a quality check on a
sample of records. Any differences in decisions were
resolved through discussion and/or by consulting a
third reviewer. Studies excluded after examination of the
full text are listed, along with the reason for exclusion,
in online supplementary appendix B1.
Data extraction and study assessment
An initial network was developed incorporating all the
identiﬁed trials. This was then adapted for each
outcome, following the feasibility assessment, to reﬂect
the trials that actually reported data for that outcome.
NMA requires that the identiﬁed studies are suitably
homogeneous to facilitate reliable comparison.19 Data
were extracted from the studies to inform both this simi-
larity assessment and the outcome analyses for the net-
works developed. One reviewer extracted key study
characteristics relating to study methods, populations,
trial settings, treatments and outcomes using a standar-
dised data extraction form, and a second reviewer
checked each extraction. Any discrepancies were
resolved by discussion, or with the input of a third
reviewer. The similarity of the candidate studies was
assessed using a modiﬁed version of the tool developed
by the Australian Pharmaceutical Beneﬁts Advisory
Committee (PBAC)20 (see online supplementary
appendix C1).
Heterogeneity assessment
For each outcome, statistical heterogeneity was assessed
for each pairwise treatment comparison informed by at
least two trials. Heterogeneity was measured by the I2
statistic, where I2 values of 25%, 50% and 75% were con-
sidered to indicate low, moderate and high heterogen-
eity, respectively.21
Network meta-analysis
The analysis focused on the licensed doses of
onabotulinumtoxinA (100 U) and mirabegron (25 and
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50 mg), although studies evaluating any dosages were eli-
gible to contribute to the networks where they provided
links between the licensed doses through a common
comparator. Networks were developed for each of the
seven outcomes, based on quality of study methods, con-
founding factors (participants and circumstances),
common treatment arms and outcomes (see online sup-
plementary appendices C2–C7). Studies that were con-
sidered similar based on the modiﬁed PBAC tool
(detailed in online supplementary appendix C1) and
reported sufﬁcient data at 12 weeks were included in the
NMAs; those that neither compared key treatments nor
provided indirect information did not contribute to the
networks. For change from baseline outcomes, studies
with no information on the mean baseline values (of the
outcome) could not be included in the network meta-
regressions (NMRs). The outcomes of interest were: pro-
portions of patients achieving 100% and 50% reduction
from baseline in the number of UI episodes per day;
mean change in UI episodes per day; proportion of
patients achieving 100% reduction from baseline in the
number of urgency episodes per day; mean change in
urgency episodes per day; mean change in the
Table 1 Eligibility criteria for network meta-analysis
PICOS
element Inclusion criteria Exclusion criteria
Population ▸ Adults (≥18 years);
▸ Idiopathic overactive bladder, with/without
urinary incontinence;
▸ Conditions described as:
– Refractory detrusor overactivity;
– Idiopathic urge urinary incontinence;
– Non-neurogenic urge urinary
incontinence.
▸ Patients with overactive bladder and urinary incontinence
with a known cause (eg, surgery, pregnancy, benign
prostatic hyperplasia, bladder outlet obstruction;
▸ Neurogenic overactive bladder;
▸ Stress urinary incontinence;
▸ Bladder oversensitivity;
▸ Bladder hypersensitivity;
▸ Mixed populations where results not reported separately
for idiopathic overactive bladder subgroup.
Intervention ▸ OnabotulinumtoxinA (all doses);
▸ Mirabegron (all doses).
Other variants of botulinum toxin such as Dysport
(abobotulinumtoxinA).
Comparator ▸ OnabotulinumtoxinA;
▸ Mirabegron;
▸ Sacral nerve stimulation;
▸ Percutaneous tibial nerve stimulation;
▸ Anticholinergics (including solifenacin/
tolterone);
▸ Sham treatments;
▸ Placebo;
▸ Best supportive care.
Other variants of botulinum toxin such as Dysport
(abobotulinumtoxinA).
Outcomes ▸ Episodes of urinary incontinence:
– Change in number of episodes;
– Proportion of patients who achieve
≥50% reduction in number of episodes
▸ Urinary frequency;
▸ Urgency;
▸ Nocturia.
Study design ▸ Randomised controlled trials;
▸ Cross-over randomised controlled trials if
data reported at cross-over.
▸ Retrospective studies;
▸ Non-English reports;
▸ Abstracts/conference presentations.
PICOS, Population/Patients, Interventions, Comparators/Control, Outcomes, Study design.
Figure 1 Study flow diagram. NMA, network meta-analysis.
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frequency of urination per day; mean change in the
number of nocturia episodes per night.
Standard Bayesian NMA was applied to all outcomes.22
Both ﬁxed-effects and random-effects models were con-
ducted, but only random-effects models are presented in
this publication because they account for heterogeneity
in the treatment effects between studies. For some UI
and urgency outcomes, differences in baseline severity
between the mirabegron and onabotulinumtoxinA trials
were identiﬁed. For each of these outcomes, individual
patient data from two onabotulinumtoxinA trials23 24
were used to explore the relationship between baseline
severity and treatment effect. Generalised linear models
were used to assess whether there was a linear relation-
ship between baseline severity and the treatment effect
(OR for binomial outcomes, mean difference in change
from baseline for continuous outcomes) for
onabotulinumtoxinA compared with placebo. Where
baseline severity had a statistically signiﬁcant impact on
the treatment effect, random-effects NMR was applied in
addition to the NMA (further details of both the NMA
and the NMR are included in online supplementary
appendices D–D1). All analyses were conducted using
WinBUGS V.1.4.3.25 Relative treatment effects are sum-
marised by point estimates and 95% credible intervals
(CrIs; CrIs are the Bayesian analogue of CIs; for the
binomial outcomes, CrIs that exclude 1 suggest a differ-
ence between treatments; for the continuous outcomes,
CrIs that exclude 0 suggest a difference between treat-
ments). For each NMR, the relative treatment effects are
reported based on the average baseline severity of the
participants included in the network (ie, 3.48 episodes
per day for UI and 6.32 episodes per day for urgency).
RESULTS
Included studies
The search process yielded 2501 studies of which 19
met the inclusion criteria: 11 studies assessed
onabotulinumtoxinA23 24 26–34 and 8 studies assessed
mirabegron.35–42
All of the included trials were conducted postyear
2000 and none of them directly compared
onabotulinumtoxinA with mirabegron. The study
methods were not described in sufﬁcient detail for 13 of
the 19 trials included in the review. All but two trials26 28
were reported to be double-blind, and only six
studies reported adequate concealment of random-
isation.32–34 36 40 42 The majority of studies reported
a treatment period of 12 weeks, with follow-up ranging
from 2 to 24 weeks or 6 months. Where reported (15
studies), loss to follow-up ranged from 0%26 32 to
18.4%30 in studies of onabotulinumtoxinA and from
4.7%39 to 23.6%41 in studies of mirabegron. The study
summary data are shown in table 2 and further details
are reported within the similarity assessment in online
supplementary appendices C2–C7.
Patient baseline characteristics were not reported in
detail for all of the included studies. Participants’
characteristics were considered within the similarity
assessment (see online supplementary appendix C5).
The participants were predominantly female (55.9
−100%) and had experienced OAB for 40.6–94 months.
Patients in the mirabegron and onabotulinumtoxinA
studies differed at baseline in the severity of their symp-
toms with a lower average number of daily UI episodes
and urgency episodes observed in mirabegron studies
(1−3 UI episodes and 4.5−6 urgency episodes) com-
pared with onabotulinumtoxinA studies (5−6 UI epi-
sodes and 7−9 urgency episodes). Prior therapy for
OAB (drugs or continence surgery) was not reported
consistently across the studies.
Similarity assessment
The trials were broadly similar in terms of trial method-
ology, confounding factors in relation to participant
populations and circumstances, and treatment arms (see
online supplementary appendices C2–C7). However,
some notable differences were identiﬁed that could
affect potential inclusion in an indirect treatment com-
parison: differences in treatment period, severity of
symptoms, prior therapy and treatment administration
(details in online supplementary appendices C5–C7).
Possible networks
All trials that contributed data to at least one outcome
are shown in the network diagram (ﬁgure 2), although
the actual networks for each outcome differed depend-
ing on the data reported in each trial (summarised in
the online supplementary appendices E1–E2).
Assessments of heterogeneity
Pairwise comparisons of onabotulinumtoxinA 100 U
versus placebo generally had minimal to low heterogen-
eity (I2<5%), indicating that the results were similar
across all studies. For urinary frequency, moderate het-
erogeneity (I2≈50%) was observed, indicating some vari-
ation between studies above that explained by chance.
The pairwise comparison of onabotulinumtoxinA 100 vs
150 U for 100% reduction in UI episodes/day also had
moderate heterogeneity (I2≈60%). All comparisons of
mirabegron versus placebo showed minimal heterogen-
eity (table 3). In addition, the networks had no potential
for inconsistency between direct and indirect evidence.43
Network meta-analysis
Point estimates for ﬁxed-effects models were consistent
with those for random-effects models (see online
supplementary appendix F); results of random-effects
models are presented. Summary plots for
onabotulinumtoxinA versus mirabegron 50 and 25 mg
are included in ﬁgures 3 and 4 (detailed forest plots are
shown in online supplementary ﬁgures G1–G7), with
results of the analyses summarised in table 3. All out-
comes were analysed at 12 weeks.
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Table 2 Summary of characteristics of included trials
Author/trial
Study and
design
Population
(1) Mean age
(years)
(2) Female (%)
OAB inadequately
managed by
anticholinergics
Interventions/
comparators
Duration of treatment/
follow-up
BTX studies
Al Taweel26 RCT
Single centre
(Saudi Arabia)
(1) NR
(2) NR
Yes BTX: 2 doses
(200/100 U)
9 months
Brubaker27 Double-blind RCT
Multicentre (USA)
(1) 64.7–69.2
(2) 100.0
Yes BTX: 200 U
Placebo
12 months/≤1 month
Chapple23 Double-blind RCT
Multicentre
(Europe, USA)
(1) 59.2–59.5
(2) 84.5–88.1
Yes BTX: 100 U
Placebo
12 weeks/12 weeks
(non-placebo-controlled)
Cohen28 RCT
Single centre
(USA)
(1) NR
(2) NR
Yes BTX: 2 doses
(150/100 U)
24 weeks
Denys29 Double-blind RCT
Multicentre
(France)
(1) 61.6
(2) 87.9
Yes BTX: 3 doses
(150/100/50 U)
Placebo
6 months
Dmochowski30 Double-blind RCT
Multicentre
(Europe, USA,
Canada)
(1) 58.8
(2) 92.0
Yes BTX: 5 doses
(300/200/150/
100/50 U)
Placebo
36 weeks
King31 Double-blind RCT
Single centre
(Australia)
(1) 60.7–64.3
(2) 100.0
Minimal response BTX: 200 U
Placebo
6 weeks/unclear
Nitti24 Double-blind RCT
Multicentre (USA,
Canada)
(1) 61.0–61.7
(2) 88.4–90.0
Yes BTX: 100 U
Placebo
12 weeks/12 weeks
(non-placebo-controlled)
Sahai32 Double-blind RCT
Single centre
(UK)
(1) 49.8–50.8
(2) 55.9
Unclear BTX: 200 U
Placebo
12 weeks/12-week open
label extension (BTX arm
only)
Tincello33 Double-blind RCT
Multicentre (UK)
(1) 58.2–60.7
(2) 100.0
Yes BTX: 200 U
Placebo
6 months/extension study
Visco34 Double-blind RCT
Multicentre (USA)
(1) 56.7–59.3
(2) 100.0
Unclear BTX: 100 U
Anticholinergic
protocol
6 months/6 months (off
treatment)
MBG studies
ARIES35 Double-blind RCT
Multicentre (USA,
Canada)
(1) 60.1
(2) 74.3
NR MBG: 2 doses
(100/50 mg)
Placebo
12 weeks/30 days
Astellas
178-CL-04536
Double-blind RCT
Multicentre
( Japan)
(1) 54.9–56.9
(2) 80.1–85.1
NR MBG: 3 doses
(100/50/25 mg)
Placebo
12 weeks
BLOSSOM37 Double-blind RCT
Multicentre
(international)
(1) NR
(2) NR
NR MBG: 2 doses
(150/100 mg two
times daily)
Tolterodine ER
4 mg
Placebo
4 weeks/2-week placebo
follow-up
CAPRICORN38 Double-blind RCT
Multicentre
(Europe, North
America)
(1) 59.0
(2) 68.7
NR MBG: 2 doses
(50/25 mg)
Placebo
12 weeks/2 weeks
DRAGON39 Double-blind RCT
Multicentre
(international: 14
countries)
(1) 57.2
(2) 89.3
NR MBG: 4 doses
(200/100/50/
25 mg)
Placebo
12 weeks
Continued
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Urinary incontinence
100% and 50% Reduction from baseline in the number of
UI episodes/day
A logistic regression model using individual patient data
from two onabotulinumtoxinA trials23 24 showed that
continuous baseline UI severity did not have a statistic-
ally signiﬁcant effect on the OR comparing
onabotulinumtoxinA versus placebo for either 50% or
100% reduction in UI episodes/day. Hence, only stand-
ard NMA was conducted.
Across onabotulinumtoxinA trials included in the
network, complete continence was achieved by 22.9
−55% of patients receiving onabotulinumtoxinA 100 U
compared with 6.5−10.7% of the placebo group,23 24 29
and the NMA suggests that onabotulinumtoxinA 100 U
is superior to placebo. Across mirabegron trials included
in the network, full continence was achieved by 41.7
−47.1% of patients given mirabegron 25 or 50 mg vs
36.8−40.5% of the placebo group,38–40 and there was no
evidence that either of the mirabegron doses is superior
to placebo. Results of comparisons versus placebo are
reported in the online supplementary ﬁgure G1. These
results suggest that onabotulinumtoxinA 100 U is more
efﬁcacious than both doses of mirabegron in achieving
continence. Patients receiving onabotulinumtoxinA
100 U had 3.49 (CrI 1.97, 6.55) and 3.54 (CrI 1.93, 6.81)
greater odds of achieving 100% reduction in UI epi-
sodes than those receiving mirabegron 50 and 25 mg,
respectively.
Compared with placebo, higher proportions of
patients achieved a 50% reduction in daily UI episodes
with onabotulinumtoxinA 100 U (57.5−63.5% vs 28.9
−33.2%),23 24 mirabegron 50 mg (70.0−72.0% vs 59.2
−60.1%),38 40 and mirabegron 25 mg (72.8% vs
59.2%).38 For 50% reduction in UI episodes, the analysis
suggests that onabotulinumtoxinA 100 U and both
Table 2 Continued
Author/trial
Study and
design
Population
(1) Mean age
(years)
(2) Female (%)
OAB inadequately
managed by
anticholinergics
Interventions/
comparators
Duration of treatment/
follow-up
SCORPIO40 Double-blind RCT
Multicentre
(Europe,
Australia)
(1) 59.0–59.2
(2) 71.6–72.9
NR MBG: 2 doses
(100/50 mg)
Tolterodine ER
4 mg
Placebo
12 weeks/30 days
TAURUS41 Double-blind RCT
Multicentre (USA,
Europe, Canada,
South Africa, NZ,
Australia)
(1) 59.2–60.1
(2) 73.9–74.1
NR MBG: 2 doses
(100/50 mg)
Tolterodine ER
4 mg
12 months
Yamaguchi42 Double-blind RCT
Multicentre
( Japan)
(1) NR
(2) NR
NR MBG: 50 mg
Placebo
12 weeks/2 weeks
BTX, onabotulinumtoxinA; ER, extended release; MBG, mirabegron; NZ, New Zealand; NR, not reported; OAB, overactive bladder; RCT,
randomised controlled trial.
Figure 2 Network diagram showing studies contributing to the network meta-analyses.
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mirabegron doses are more efﬁcacious than placebo
(see online supplementary ﬁgure G2). While the NMA
showed that patients receiving onabotulinumtoxinA had
2.07 times greater odds (CrI 0.98, 4.49) than mirabegron
50 mg and 1.83 greater odds (CrI 0.80, 4.25) than
mirabegron 25 mg of having 50% reduction in UI epi-
sodes, these results were inconclusive. There was only a
small number of studies included in this network for
this end point (four studies involving 548–773
participants).
Table 3 Summary of outcome results for BTX (100 U) compared with MBG (50 and 25 mg)
Outcome
Heterogeneity (I2)*
(1) BTX 100 vs PBO
(2) MBG 50 vs PBO
(3) MBG 25 vs PBO
Network analysis
(method; model;
prior distribution
for between-study
precision)
Number of studies
Number of
patients
Summary effect
size (mean, 95% CrI)
Dichotomous outcomes BTX vs MBG 50 BTX vs MBG 25
Urinary incontinence
100% reduction
from baseline in
number of
episodes/day
(1) 0%
(2) 0%
(3) 0%
Standard NMA;
random effects;
informative prior
723 24 28 29 38–40
2873
OR 3.49 (1.97,
6.55)
OR 3.54 (1.93,
6.81)
50% reduction
from baseline in
number of
episodes/day
(1) 0%
(2) 0%
(3)–†
Standard NMA;
random effects;
informative prior
423 24 38 40
2462
OR 2.07 (0.98,
4.49)
OR 1.83 (0.80,
4.25)
Urgency
100% reduction
from baseline in
number of
episodes/day
(1) 0%
(2)–†
(3)–
†
Standard NMA;
random effects;
informative prior
323 24 39
1961
OR 7.01 (1.62,
32.60)
OR 6.16 (1.43,
28.58)
Continuous outcomes BTX vs MBG 50 BTX vs MBG 25
Urinary incontinence
Change from
baseline in
number of
episodes/day
(1) 0%
(2) 0%
(3) 0%
Standard NMA;
random effects; γ
prior
823 24 35 36 38–40 42
4591
Unadjusted: MD
−1.41 (−1.84,
−0.98)‡
Unadjusted: MD
−1.32 (−1.79,
−0.84)
NMR; random
effects; γ prior
6§23 24 35 36 38 40
3517
Adjusted: MD
−0.70 (−1.23,
−0.16)
Adjusted: MD
−0.62 (−1.20,
−0.02)
Urgency
Change from
baseline in
number of
episodes/day
(1) 4.6%
(2) 0%
(3) 0%
Standard NMA;
random effects; γ
prior
923 24 29 35 36 38–
40 42
6100
Unadjusted: MD
−1.48 (−2.06,
−0.92)
Unadjusted: MD
−1.63 (−2.23,
−1.03)
NMR;
random-effects; γ
prior
7§23 24 29 35 36 38 39
4390
Adjusted: MD
−1.32 (−2.00,
−0.67)
Adjusted: MD
−1.49 (−2.16,
−0.80)
Urinary frequency
Change from
baseline in
number of
episodes/day
(1) 47.7%
(2) 0%
(3) 0%
Standard NMA;
random effects; γ
prior
823 24 35 36 38–40 42
6056
MD −0.81
(−1.24, −0.40)
MD −0.89
(−1.35, −0.45)
Nocturia
Change from
baseline in
number of
episodes/night
(1) 0%
(2) 0%
(3) 0%
Standard NMA;
random effects; γ
prior
623 24 35 36 39 42
3678
MD −0.10
(−0.32, 0.12)
MD −0.06
(−0.31, 0.19)
*I2 values of 25%, 50% and 75% were considered to indicate low, moderate and high heterogeneity, respectively.21
†Not measurable since only one study informed the analysis.
‡A negative result indicates a greater mean improvement from baseline. For example, the result indicates that patients who receive BTX
100 U will improve, on average, by 1.41 episodes more than patients who receive mirabegron 50 mg.
§Two studies were excluded as they did not report baseline severity.
BTX, onabotulinumtoxinA; CrI, credible interval; MBG, mirabegron; MD, mean difference; NMA, network meta-analysis; NMR, network
meta-regression; PBO, placebo.
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Mean reduction in UI episodes/day
Analysis of individual patient data from two
onabotulinumtoxinA trials23 24 showed that baseline
number of UI episodes per day inﬂuences the mean
improvement in UI episodes relative to placebo. Thus,
in addition to the NMA, NMR was performed. The
NMR accounts for the differences in baseline UI epi-
sodes between the studies (5–6 per day for
onabotulinumtoxinA studies vs 1–3 per day for mirabe-
gron studies) and thus provides a fairer assessment of
treatment effect.
The NMA suggests that onabotulinumtoxinA 100 U
and both mirabegron doses may be more efﬁcacious
than placebo (see online supplementary ﬁgure G.3A).
In addition, onabotulinumtoxinA 100 U may be more
efﬁcacious than both mirabegron doses (table 3).
Figure 3 Summary: network meta-analysis and network metaregression for BTX 100 U versus MBG 50 mg. BTX,
onabotulinumtoxinA; MBG, mirabegron; UI, urinary incontinence.
Figure 4 Summary: network meta-analysis and network metaregression for BTX 100 U versus MBG 25 mg. BTX,
onabotulinumtoxinA; MBG, mirabegron; UI, urinary incontinence.
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For the NMR, two trials did not provide any informa-
tion on baseline severity and were therefore excluded.39 42
Under the assumptions of the NMR (see online
supplementary appendix D), the efﬁcacy of any of the
active treatments relative to placebo varies with the base-
line severity of the patient, but the relative efﬁcacy of the
active treatments does not vary with the baseline severity
of the patient. For patients with an average number of UI
episodes at baseline (3.48 UI episodes per day across all
patients included in the network), the NMR suggests that
onabotulinumtoxinA 100 U and both of the mirabegron
doses are more efﬁcacious than placebo (see online sup-
plementary ﬁgure G3B). The average reduction relative
to placebo for onabotulinumtoxinA was approximately
twice that of patients receiving mirabegron, with
onabotulinumtoxinA conferring on average a 108%
further improvement over mirabegron 50 mg, and 85%
further improvement over mirabegron 25 mg.
On average, patients receiving onabotulinumtoxinA
100 U improved by 0.70 episodes more per day than
those receiving mirabegron 50 mg (CrI 0.16, 1.23)
and by 0.62 episodes more per day than those receiv-
ing mirabegron 25 mg (CrI 0.02, 1.20). Thus,
onabotulinumtoxinA 100 U may be superior to both
of the mirabegron doses.
Urgency
100% Reduction from baseline in the number of urgency
episodes/day
One mirabegron study39 reported the proportion of
patients experiencing 100% reduction in urgency epi-
sodes (ie, no episodes at 12 weeks), and results were
derived from individual patient data from two additional
trials.23 24 Thus, three trials contributed to the network.
The NMA suggests that onabotulinumtoxinA is more
efﬁcacious than placebo for complete resolution of
urgency. There was no evidence that either of the mira-
begron doses is more efﬁcacious than placebo. Results
of comparisons versus placebo are reported in online
supplementary ﬁgure G4. The analysis also suggests that
onabotulinumtoxinA is more efﬁcacious than mirabe-
gron. Patients receiving onabotulinumtoxinA 100 U had
higher odds of resolving urgency episodes than those
receiving mirabegron 50 mg (7.01 times higher; CrI
1.62, 32.60) and mirabegron 25 mg (6.16 times higher;
CrI 1.43, 28.58).
Mean reduction in urgency episodes per day
Based on the number of urgency episodes per day at
baseline, patients in the onabotulinumtoxinA studies
were more severe than patients in the mirabegron
studies (baseline urgency episodes: 7−9 per day for
onabotulinumtoxinA studies vs 4−6 per day for mirabe-
gron studies). An analysis of individual patient data from
two onabotulinumtoxinA trials23 24 did not ﬁnd a statis-
tically signiﬁcant relationship between baseline urgency
and treatment effect. However, an NMR was performed,
in addition to an NMA, to ensure that the differences in
baseline severity did not affect the results.
The results of the NMA and NMR are similar (note
that two trials did not provide any information on base-
line severity and were therefore excluded from the
NMR40 42). The NMA suggests that all of the active treat-
ments are more efﬁcacious than placebo (see online
supplementary ﬁgure G5A). Based on the average sever-
ity at baseline across all patients included in the
network, the NMR supports this conclusion (see online
supplementary ﬁgure G5B). The average reduction rela-
tive to placebo for onabotulinumtoxinA is at least three
times that of patients receiving mirabegron after adjust-
ing for baseline severity of urgency symptoms, with
onabotulinumtoxinA conferring, on average, approxi-
mately three times the reduction due to mirabegron
50 mg and four times the reduction due to mirabegron
25 mg. Both analyses suggest that onabotulinumtoxinA
100 U is more efﬁcacious than either mirabegron 50 or
25 mg in reducing urgency episodes. The NMR suggests
that patients improved, on average, by 1.32 (CrI 0.67,
2.00) and 1.49 (CrI 0.80, 2.16) episodes more per day
on onabotulinumtoxinA 100 U compared with mirabe-
gron 50 and 25 mg, respectively.
Urinary frequency
At baseline, severity of urinary frequency was similar
across patients in the onabotulinumtoxinA and mirabe-
gron trials. NMA suggests that each of the active treat-
ments is more efﬁcacious than placebo (see online
supplementary ﬁgure G6). The analysis also suggests
that onabotulinumtoxinA is more efﬁcacious than both
mirabegron doses in reducing the mean number of
urination episodes per day. On average, patients receiv-
ing onabotulinumtoxinA 100 U improved by 0.81 epi-
sodes more than patients on mirabegron 50 mg (CrI
0.40, 1.24) and by 0.89 episodes more than those on
mirabegron 25 mg (CrI 0.45, 1.35).
Nocturia
Baseline severity was similar across the
onabotulinumtoxinA and mirabegron trials. Each of the
active treatments was shown to be more efﬁcacious than
placebo, with the mean reduction in nocturia episodes
per night, relative to placebo, greater for patients receiv-
ing onabotulinumtoxinA 100 U (0.25; CrI 0.07, 0.43)
than for patients receiving mirabegron 50 mg (0.15; CrI
0.03, 0.27) and mirabegron 25 mg (0.19; CrI 0.02, 0.36;
see online supplementary ﬁgure G7). However, while
estimates of the mean treatment effects favoured
onabotulinumtoxinA, there was no conclusive evidence
of a difference between onabotulinumtoxinA 100 U and
either mirabegron 50 mg (mean reduction 0.10; CrI
−0.12, 0.32) or mirabegron 25 mg (mean reduction
0.06; CrI −0.19, 0.31) for the nocturia end point.
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DISCUSSION
Until 2012, patients being treated for OAB progressed
along a clinical pathway of ﬁrst-line conservative
therapy which included lifestyle interventions and
behavioural techniques, followed by second-line treat-
ment with cycling on anticholinergics, then third-line
treatments such as sacral neuromodulation, percutan-
eous tibial nerve stimulation, and off-label use of
onabotulinumtoxinA. With regard to anticholinergics,
there is known efﬁcacy and safety but no clear evi-
dence of superiority of one agent over another. In
addition, long-term adherence is a problem secondary
to adverse effects and insufﬁcient efﬁcacy.44 The
recent approval of two new treatments—mirabegron
and onabotulinumtoxinA—are viable alternatives to
trying multiple anticholinergics, and they also allow
for potential improved management of OAB symp-
toms. Pivotal trials of both treatments, all sponsored
by their manufacturers, have shown their superiority
over placebo.23 24 30 35 38 40
Using NMA, the current review combined all relevant
evidence available, on the treatment of adults with idio-
pathic OAB with licensed doses of onabotulinumtoxinA
and mirabegron. In the absence of direct comparative
evidence, seven efﬁcacy outcomes were addressed in the
indirect treatment comparison, each outcome including
between three and nine studies. Although only the
results of random-effects models are reported,
ﬁxed-effects models were also explored. Point estimates
were consistent but the degree of uncertainty around
the estimates was somewhat greater for the
random-effects models, indicating some potential for
heterogeneity among the studies (see online
supplementary appendix F). Results from the network
analyses suggest that onabotulinumtoxinA 100 U is more
efﬁcacious than mirabegron (50 and 25 mg doses) in
improving the following OAB parameters: UI episodes
per day, 100% reduction in UI, urgency episodes per
day, 100% reduction in urgency and urinary frequency.
Studies included in the analyses typically assessed short-
term outcomes (12–13 weeks) as dictated by regulatory
agencies; longer term efﬁcacy of onabotulinumtoxinA
versus mirabegron cannot be extrapolated from the data
reported.
NMA involves pooling of trials and is subject to some
of the same limitations as pairwise meta-analysis, such
as quality of the individual studies and publication bias.
A key consideration of any NMA is whether the identi-
ﬁed studies are sufﬁciently similar to facilitate reliable
comparison on an outcome of interest. The
onabotulinumtoxinA and mirabegron trials were com-
pared in terms of quality of study methods, patient
populations, treatments and outcome measures. While
the trials were broadly similar in terms of key study
characteristics, there were notable differences. For
example, the methodology of each individual trial
could not be fully assessed for risk of bias given the
limited information available, the majority of trials had
been sponsored by the manufacturers, and not all
studies reported the same degree of information. The
quality and methods of the randomised trials were
therefore assessed using the PBAC tool, which consid-
ers adequacy of allocation concealment, reported
blinding, duration of study and loss to follow-up (sum-
marised in the online supplementary appendix C2).
Having only a few studies in the ﬁnal networks meant
that for some outcomes the analysis had limited power
to detect a difference between the two active treat-
ments, as reﬂected in the wide CrIs on some compara-
tive treatment effects.
There were differences in the proportion of females in
the onabotulinumtoxinA studies (55.4–100%) compared
with the mirabegron studies (68.7–89.3%), with all but
one of the onabotulinumtoxinA studies involving a larger
percentage of women. This NMA has made the assump-
tion that sex does not affect response to treatment.
Patients in the onabotulinumtoxinA trials had more
severe UI and urgency symptoms at baseline than those
in the mirabegron trials and all patients in the
onabotulinumtoxinA trials had failed antimuscarinic
therapy. Our logistic regression model assessed the
impact of continuous baseline UI severity on OR
(onabotulinumtoxinA vs placebo) and suggested that
continuous baseline UI severity did not signiﬁcantly
impact the OR for either 50% or 100% reduction in UI
episodes/day. However, a recent analysis of the effect of
categorical baseline UI severity on 100% reduction in UI
episodes/day did show a trend for increasing OR
(onabotulinumtoxinA vs placebo) with increasing cat-
egorical baseline UI severity.45 The NMR model that we
used adjusts for the baseline severity by assuming a linear
relationship between baseline severity and change from
baseline. This assumption was tested using individual
patient data from two onabotulinumtoxinA trials. The
assumption held up in this test but should still be consid-
ered a limitation of the analysis given that such patient-
level data were not available for mirabegron trials. Based
on the data available, this approach was the most prag-
matic approach possible. The treatments themselves also
differ in their mode of administration:
onabotulinumtoxinA and the placebo in the
onabotulinumtoxinA trials were administered as a single
procedure, while both mirabegron and placebo were
administered as daily oral tablets in the mirabegron trials.
In order to produce a connected network for the pur-
poses of the analyses it was assumed that the placebo
treatments would be equally effective when administered
to the same populations.46 We recognise that this assump-
tion is potentially a source of bias in the NMA.
The NMA was informed by extensive searches con-
ducted across a range of information sources. Since only
English language studies were speciﬁed in the protocol,
studies published in other languages were not included
in this review. The review may also be subject to publica-
tion bias; the potential impact of this was not explored
further.
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Both onabotulinumtoxinA and mirabegron have side
effects associated with treatment, albeit the adverse
effect proﬁles are different from those of antimuscarinic
agents.44 Most common side effects with mirabegron
include hypertension, nasopharyngitis, urinary tract
infection and headache, while onabotulinumtoxinA is
associated with urinary tract infections, dysuria, urinary
retention, bacteriuria, and increased residual urine
volume. Currently, there is little evidence comparing the
safety of mirabegron and onabotulinumtoxinA with
other interventions for OAB. The current analysis did
not address adverse events with either compound, which
represents a limitation of the review.
There is less literature relating to the treatment of
OAB with approved doses of onabotulinumtoxinA and
mirabegron, probably because they are newer treat-
ments. A Cochrane review that aimed to establish the
comparative effectiveness of intravesical botulinum toxin
with other treatments for neurogenic and idiopathic
OAB identiﬁed only one study which compared
onabotulinumtoxinA with another active treatment
(intravesical resinferatoxin).47 Two meta-analyses, which
combined results from the various phase III trials of mir-
abegron,48 49 reported the short-term effectiveness of
mirabegron 50 mg compared with placebo, and a recent
mixed treatment comparison of medical treatments for
OAB identiﬁed six studies of mirabegron 50 mg.17
This research adds information to the current evi-
dence base and, to the best of our knowledge, repre-
sents the ﬁrst evaluation comparing the relative beneﬁts
of onabotulinumtoxinA and mirabegron. This study will
hopefully assist patients and healthcare providers in
making more informed decisions with regard to OAB
treatment options. Future research building on these
existing networks with other treatments for OAB, appro-
priate to the severity of the patients’ OAB symptoms and
corresponding phase of treatment, will continue to aid
in the treatment selection process.
CONCLUSIONS
OnabotulinumtoxinA and mirabegron have recently
received marketing authorisations for patients with OAB
and offer potential alternatives to management with
anticholinergic therapy in patients with inadequately
managed symptoms. In this indirect treatment
comparison, baseline differences between the
onabotulinumtoxinA and mirabegron studies were
adjusted using NMR. Results of this NMR suggest that,
compared with mirabegron, onabotulinumtoxinA is asso-
ciated with additional reductions in the number of UI
episodes and urgency episodes per day and daily urinary
frequency in patients with idiopathic OAB at 12 weeks. In
addition, more patients receiving onabotulinumtoxinA
experience a 100% reduction in UI and 100% reduction
in urgency than patients receiving mirabegron.
OnabotulinumtoxinA is a promising therapeutic alter-
native for patients that have failed anticholinergic
treatment. There is a need for more supporting evi-
dence from well-conducted, head-to-head comparisons
of onabotulinumtoxinA and other therapies evaluating
outcomes and adverse effects over both the short and
long term.
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